<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3282">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047201</url>
  </required_header>
  <id_info>
    <org_study_id>EHNCTE-1309</org_study_id>
    <nct_id>NCT02047201</nct_id>
  </id_info>
  <brief_title>Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC</brief_title>
  <official_title>Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <authority>Lithuania: Bioethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of cisplatin plus intensity-modulated radiotherapy
      (IMRT) based on FDG-PET/CT after induction chemotherapy (IC) for locally advanced head and
      neck squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour metabolic response</measure>
    <time_frame>2 weeks after IC</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the tumour metabolic response (complete metabolic response [CMR], partial metabolic response [PMR], stable metabolic disease [SMD] or progressive metabolic disease [PMD]) to induction chemotherapy (IC) as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour anatomic response</measure>
    <time_frame>2 weeks after IC</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the tumour anatomic response (complete response [CR], partial response [PR], stable disease [SD] or progressive disease [PD]) to induction chemotherapy (IC) as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUVmax and SUVav variations</measure>
    <time_frame>2 weeks after IC</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare SUVmax and SUVav as assessed by FDG-PET/CT performed at baseline and 2 weeks after IC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 monhts from chemoradiotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate acute and late toxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall tumor metabolic and anatomic response correlation</measure>
    <time_frame>Baseline and 2 weeks after IC</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the correlation of tumor metabolic response as assessed by FDG-PET/CT with the anatomic tumor response rate as assessed by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), progression free survival (PFS), loco regional control (LRC) correlation</measure>
    <time_frame>12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the correlation of overall survival (OS), progression free survival (PFS), loco regional control (LRC) with metabolic tumor response, anatomic tumor response, baseline SUV and Human papillomavirus (HPV).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>intensity-modulated radiation theraphy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Assessing tumor response using FDG-PET/CT.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Positron emission tomography-computed tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Taxotere, Docefrez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>5-Fluorouracil, Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 years or over;

          -  Histologically confirmed locally advanced (stage III and IV) head and neck squamous
             cell carcinoma  (HNSCC);

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

          -  Signed written informed consent approved by the Lithuanian Bioethics Committee
             (LBEC);

        Exclusion Criteria:

          -  Positive serum pregnancy test in women of childbearing potential or breastfeeding;

          -  Presence of distant metastasis;

          -  Second primary tumor;

          -  History of other malignancy within the last 5 years;

          -  Recurrent head and neck cancer;

          -  Serious uncontrolled concomitant disease that would contraindicate the use of any
             drugs use in this study as chemotherapy or radiotherapy;
                                 ;

          -  Inadequate organ function, evidenced by the following laboratory results:

               1. Absolute neutrophil count &lt;1,500 cells/mm3;

               2. Platelet count &lt;100,000 cells/mm3;

               3. Hemoglobin &lt;9 g/dL;

               4. Total bilirubin greater than the upper limit of normal (ULN);

               5. AST (SGOT) or ALT (SGPT) &gt;1,5 x ULN;

               6. Alkaline phosphatase levels &gt;2,5 x the ULN;

               7. Serum creatinine &gt;2,0 mg/dl or 177 umol/l.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilona Kulakiene, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lithuanian University of Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilona Kulakiene, Professor</last_name>
    <phone>+37037787340</phone>
    <email>kulakiene@dr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-44307</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remigijus Zaliunas, Professor</last_name>
      <phone>+37037327200</phone>
      <email>rektoratas@lsmuni.lt</email>
    </contact>
    <investigator>
      <last_name>Ilona Kulakiene, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Severina Sediene, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktoras Rudzianskas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vita Simonyte, Resident</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Ilona Kulakiene</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>PET/CT</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>IMRT</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
